en sv

NextCell Pharma AB comments on the trading halt of 25 April 2019


Cellaviva Sverige - April 26, 2019 - 0 comments

With respect to Spotlight Stock Market’s decision on 25 April 2019 to halt trading in NextCell Pharma AB’s share, the stock market has, in accordance with its regulations, ordered the company to comment on the trading halt.

Discussions are currently underway between the boards of NextCell Pharma AB and Idogen AB regarding a potential merger. The structure being discussed would entail that NextCell Pharma AB makes a bid for all of the shares in Idogen AB and in turn will offer its own shares as a means of payment. At the time of the press release, the dialogue between the companies has only just begun and NextCell Pharma AB’s Board of Directors intends to publish more information some time during the forthcoming week.

This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on 26 April 2019.

Stay up to date with the latest development in NextCell Pharma

LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Sofia Fredrikson, CFO

Phone: 08-735 5595

E-mail: info@nextcellpharma.com

www.nextcellpharma.com